about
Detection of populations at risk using drug monitoring data.Modulation of the benzodiazepine-GABA receptor chloride ionophore complex by multiple allosteric sites: evidence for a barbiturate "receptor".Basic and clinical aspects of the activity of the new monoamine oxidase inhibitors.Beta-carbolines as tools in memory research: human data with the beta-carboline ZK 93426.Beta-carbolines as tools in memory research: animal data and speculations.Power analysis for correlation of plasma level and clinical data.Testing the efficacy of new neuroleptic drugs.Evaluating antidepressants and anxiolytics.Measuring the efficacy of psychotropic drugs: clinical symptoms and rating scales.Methodological problems in assessing quality of life as outcome in psychopharmacology: a multiaxial approach.Ascertainment of side effects in psychopharmacologic clinical trials.Diagnoses as selection criteria in drug trials.Functional classification and response to psychotropic drugs.Evaluation of drugs in Alzheimer's disease and age-associated memory impairment.Testing the efficacy of new hypnotic drugs.Placebo-controlled studies in depression: necessity and feasibility.Statistical issues: sample size and dropout.French experiences with the Hamilton scales in comparison with other scales for depression and anxiety.Use of the Hamilton Depression Scale in general practice.The Hamilton Depression Scale and its alternatives: a comparison of their reliability and validity.Psychometric developments of the Hamilton scales: the spectrum of depression, dysthymia, and anxiety.Selective dopamine D1 and D2 receptor antagonists.Benzodiazepine receptor subtypes and their possible clinical significance.Neuroleptic drug levels in erythrocytes and in plasma: implications for therapeutic drug monitoring.Active metabolites of neuroleptics in plasma and CSF: implications for therapeutic drug monitoring.Plasma level monitoring for maintenance neuroleptic therapy.Neurotransmitter interactions as a target of drug action.Negative symptoms in schizophrenia: a target for new drug development.Models of memory: information processing.Histamine H3 receptors in the brain: potent and selective ligands.Animal pharmacology of raclopride, a selective dopamine D2 antagonist.Genetic polymorphisms of drug-metabolizing enzymes: molecular mechanisms.Genetic polymorphism in drug oxidation.The use of human liver banks in pharmacogenetic research.Inhibitors of the microsomal oxidation of psychotropic drugs: selectivity and clinical significance.Pharmacokinetic and clinical significance of genetic variability in psychotropic drug metabolism.Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators.Role of pharmacogenetics in drug development.Clinical implications of the pharmacokinetics of tricyclic antidepressants.Hydroxy metabolites of tricyclic antidepressants: evaluation of relative cardiotoxicity.
P1433
Q30945374-E1815AA4-D8BE-4D7B-9583-74D770627B1BQ34163025-9647DF88-46E5-4D2B-8474-8B72E2EC625BQ34163800-BB2E34C1-960A-4A50-9B04-8C953CA74ACEQ34164829-6030F8E3-40E7-4E98-B4B1-1320FCD7AA14Q36428994-2FBCE368-3A21-4A83-AC8A-74DB72377F2FQ36741758-269162DF-809E-4605-A64E-64A04EE06FE0Q37594254-AD5730EB-F89F-4AAB-9EE7-E28C9D410EABQ37594262-F6C98DBF-BD91-4478-9772-80C93193E23EQ37943871-258E8D94-EC1B-49E4-BDEE-401B9C3561F3Q37943872-42CE6810-CD41-4482-AFAB-A6DC889592D3Q37943874-60158123-0EC8-4FDD-B97E-69598142EEA6Q37943876-E095A12F-C033-4A4C-BEC8-7373109CD9AFQ37943878-124979B8-1A0F-4CC5-85B8-97D87C0F6548Q37943879-B3B11BEB-AE00-41A0-A331-EBB66D8C81BEQ37943880-A79658EA-EEFA-40F5-9BC2-FEC8A56E83A8Q37943881-52C7CE0B-91E6-42E2-A487-A40BBBEEEAFBQ37943882-73C3DD63-6592-4A71-B14C-767B75EB92E9Q37952162-E7C5D604-6EC2-4FE3-9C30-5CB4D404ED30Q37952165-8A902C86-2EEC-4E13-89CC-437D9DB36A92Q37952167-1E9E97C0-3FBA-4593-9232-944EC0CD005FQ37952168-865EE118-0357-4B6B-95CD-A26960D0C728Q38368262-EA560598-15DB-47E2-80E1-8FC21D4CC6FFQ38368266-40EAADC1-63D9-4EA8-864F-FDA8963DCA9EQ38368272-BF7C5674-AFC6-4EB8-944E-B9237AAB602AQ38368278-E43EEA92-B7EE-45D4-BB66-5D7A920A7099Q38368280-A9C45AB3-BCEB-4F49-8849-E53D8036A048Q38368290-307DAE92-7A51-4183-B976-51417A39FEEEQ38368292-47D8E7E2-67B6-48FA-AFA5-995F340466E2Q38487759-74A682F6-3EA1-4167-9235-47EF5821638DQ38734070-C6C6C424-9A89-453E-A7C5-CDB18694CB38Q38734073-FDEE044B-6490-458F-AB35-6B4E6A641A01Q38734077-B40CED80-CCEC-4901-9B17-FA772EA3D57EQ38734088-4B8281FA-0CE8-402F-9056-B90FC3162C15Q38734100-509031C1-1FA5-4AFB-97BE-A43CC2312A42Q38734111-6BB407A4-61E2-489C-9678-C28EBE1CD08EQ38734126-88513894-1A02-475A-9CC6-888B43F6078EQ38734128-6B55AE3C-54E8-4C2A-BE01-E2765F71F56FQ38734131-270C2A98-8C44-4C58-900F-33E268BC2B94Q38734135-1428E9E2-7243-4760-B294-EF0AF5ABEE75Q38734145-048D59EB-5867-467E-B505-CA591EF9E43C
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift van Springer Science+Business Media
@nl
wissenschaftliche Fachzeitschrift
@de
name
Psychopharmacology series
@ast
Psychopharmacology series
@en
Psychopharmacology series
@es
Psychopharmacology series
@it
Psychopharmacology series
@nl
type
label
Psychopharmacology series
@ast
Psychopharmacology series
@en
Psychopharmacology series
@es
Psychopharmacology series
@it
Psychopharmacology series
@nl
altLabel
Psychopharmacol Ser
@en
prefLabel
Psychopharmacology series
@ast
Psychopharmacology series
@en
Psychopharmacology series
@es
Psychopharmacology series
@it
Psychopharmacology series
@nl
P1055
P1156
P1476
Psychopharmacology series
@en